; Whereas an estimated 100,000 individuals have SCD in the United States, with 1 out of every 365 African-American births and 1 out of every 16,300 Hispanic-American births resulting in SCD, and nearly 1 out of 13 African-American babies are born with SCT; Whereas SCD affects millions of individuals throughout the world, especially individuals of genetic descent from sub-Saharan regions of Africa, South America, the Caribbean, Central America, Saudi Arabia, India, Turkey, Greece, and Italy; Whereas the variance relating to disease prevalence of SCT ranges greatly by region, with rates as high as 40 percent in certain regions of sub-Saharan Africa, eastern Saudi Arabia, and central India; Whereas, in many countries that are poor in resources, more than 90 percent of children with SCD do not live to see adulthood; Whereas approximately 1,000 children in Africa are born with SCD each day, more than 1/2 of whom will die before their fifth birthday; Whereas the high prevalence of SCD in the central and western regions of India results in approximately 20 percent of babies diagnosed with SCD in those regions dying before the age of 2; Whereas, in 2006, the World Health Assembly passed a resolution, adopted by the United Nations in 2009, recognizing SCD as a public health priority with a call to action for each country to implement measures to tackle the disease; Whereas screening newborns for SCD is a crucial first step for families to obtain a timely diagnosis, to obtain comprehensive care, and to decrease the mortality rate for children with respect to SCD; Whereas approved treatments for SCD are limited, with the Food and Drug Administration approving only 4 SCD therapies since 2017, but, as of the date of adoption of this resolution, there are more than 40 SCD therapies in development; Whereas there is an immediate need for lifesaving therapeutics that can improve the duration and quality of life for individuals with SCD